| 11. |
- Kostyleva, D., et al.
(författare)
-
Towards the Limits of Existence of Nuclear Structure: Observation and First Spectroscopy of the Isotope K-31 by Measuring Its Three-Proton Decay
- 2019
-
Ingår i: Physical Review Letters. - 1079-7114 .- 0031-9007. ; 123:9
-
Tidskriftsartikel (refereegranskat)abstract
- The most remote isotope from the proton dripline (by 4 atomic mass units) has been observed: K-31. It is unbound with respect to three-proton (3p) emission, and its decays have been detected in flight by measuring the trajectories of all decay products using microstrip detectors. The 3p emission processes have been studied by the means of angular correlations of S-28 + 3p and the respective decay vertices. The energies of the previously unknown ground and excited states of K-31 have been determined. This provides its 3p separation energy value S-3p of -4.6(2) MeV. Upper half-life limits of 10 ps of the observed K-31 states have been derived from distributions of the measured decay vertices.
|
|
| 12. |
- Mukha, I. G., et al.
(författare)
-
Deep excursion beyond the proton dripline. I. Argon and chlorine isotope chains
- 2018
-
Ingår i: Physical Review C. - 2469-9993 .- 2469-9985. ; 98:6
-
Tidskriftsartikel (refereegranskat)abstract
- The proton-unbound argon and chlorine isotopes have been studied by measuring trajectories of their decay-in-flight products by using a tracking technique with microstrip detectors. The proton (1p) and two-proton (2p) emission processes have been detected in the measured angular correlations "heavy-fragment"+p and "heavy-fragment"+p+p, respectively. The ground states of the previously unknown isotopes Cl30 and Cl28 have been observed for the first time, providing the 1p-separation energies Sp of -0.48(2) and -1.60(8), MeV, respectively. The relevant systematics of 1p- and 2p-separation energies have been studied theoretically in the core+p and core+p+p cluster models. The first-time observed excited states of Ar31 allow one to infer the 2p-separation energy S2p of 6(34) keV for its ground state. The first-time observed state in Ar29 with S2p=-5.50(18) MeV can be identified as either a ground state or an excited state according to different systematics.
|
|
| 13. |
- Mukha, I., et al.
(författare)
-
Observation and Spectroscopy of New Proton-Unbound Isotopes Ar-30 and Cl-29: An Interplay of Prompt Two-Proton and Sequential Decay
- 2015
-
Ingår i: Physical Review Letters. - 1079-7114 .- 0031-9007. ; 115:20, s. 7-
-
Tidskriftsartikel (refereegranskat)abstract
- Previously unknown isotopes Ar-30 and Cl-29 have been identified by measurement of the trajectories of their in-flight decay products S-28 + p + p and S-28 + p, respectively. The analysis of angular correlations of the fragments provided information on decay energies and the structure of the parent states. The ground states of Ar-30 and Cl-29 were found at 2.25(-0.10)(+0.15) and 1.8 +/- 0.1 MeV above the two-and one-proton thresholds, respectively. The lowest states in Ar-30 and Cl-29 point to a violation of isobaric symmetry in the structure of these unbound nuclei. The two-proton decay has been identified in a transition region between simultaneous two-proton and sequential proton emissions from the Ar-30 ground state, which is characterized by an interplay of three-body and two-body decay mechanisms. The first hint of a fine structure of the two-proton decay of Ar-30*(2(+)) has been obtained by detecting two decay branches into the ground and first-excited states of the S-28 fragment.
|
|
| 14. |
- Nociforo, C., et al.
(författare)
-
Shell Closure N=16 in O-24
- 2009
-
Ingår i: AIP Conference Proceedings. - 1551-7616 .- 0094-243X. ; 1165, s. 90-93 461
-
Konferensbidrag (refereegranskat)abstract
- Advanced nuclear structure models predict the presence of the shell closures N=14, 16 in neutron-rich O isotopes rather than N=20. Spectroscopic investigations performed at the neutron drip line have recently confirmed such predictions showing that the O-24 is a doubly magic nucleus (Z=8, N=16). Predictions within the shell model calculation for the O-23,O-24 ground state have been confirmed measuring their spectroscopic factors. Results obtained in one-neutron removal reactions performed by using in-flight radioactive ion beams produced at the Fragment Separator FRS of GSI are reported.
|
|
| 15. |
- Horvath, I., et al.
(författare)
-
A European Respiratory Society technical standard: exhaled biomarkers in lung disease
- 2017
-
Ingår i: European Respiratory Journal. - : European Respiratory Society (ERS). - 0903-1936 .- 1399-3003. ; 49:4
-
Tidskriftsartikel (refereegranskat)abstract
- Breath tests cover the fraction of nitric oxide in expired gas (FeNO), volatile organic compounds (VOCs), variables in exhaled breath condensate (EBC) and other measurements. For EBC and for FeNO, official recommendations for standardised procedures are more than 10 years old and there is none for exhaled VOCs and particles. The aim of this document is to provide technical standards and recommendations for sample collection and analytic approaches and to highlight future research priorities in the field. For EBC and FeNO, new developments and advances in technology have been evaluated in the current document. This report is not intended to provide clinical guidance on disease diagnosis and management. Clinicians and researchers with expertise in exhaled biomarkers were invited to participate. Published studies regarding methodology of breath tests were selected, discussed and evaluated in a consensus-based manner by the Task Force members. Recommendations for standardisation of sampling, analysing and reporting of data and suggestions for research to cover gaps in the evidence have been created and summarised. Application of breath biomarker measurement in a standardised manner will provide comparable results, thereby facilitating the potential use of these biomarkers in clinical practice.
|
|
| 16. |
- Brinkman, P, et al.
(författare)
-
Exhaled volatile organic compounds as markers for medication use in asthma
- 2020
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 55:2
-
Tidskriftsartikel (refereegranskat)abstract
- Asthma is a heterogeneous condition, characterised by chronic inflammation of the airways, typically managed with inhaled bronchodilators and corticosteroids. In the case of uncontrolled asthma, oral corticosteroids (OCSs) are often prescribed. Good adherence and inhalation technique are associated with improved outcomes; however, it is difficult to monitor appropriate drug intake and effectiveness in individual patients. Exhaled breath contains thousands of volatile organic compounds (VOCs) that reflect changes in the body's chemistry and may be useful for monitoring drug pharmacokinetics/pharmacodynamics. We aimed to investigate the association of exhaled VOCs in severe asthma patients from the U-BIOPRED cohort (by gas chromatography coupled with time-of-flight mass spectrometry) with urinary levels of salbutamol and OCSs (by liquid chromatography coupled with high-resolution mass spectrometry).MethodsSamples were collected at baseline and after 12–18 months of follow-up. Statistical analysis was based on univariate and multivariate modelling, followed by area under the receiver operating characteristic curve (AUC) calculation. Results were verified through longitudinal replication and independent validation.ResultsData were available for 78 patients (baseline n=48, replication n=30 and validation n=30). Baseline AUC values were 82.1% (95% CI 70.4–93.9%) for salbutamol and 78.8% (95% CI 65.8–91.8%) for OCS. These outcomes could be adequately replicated and validated. Additional regression analysis between qualified exhaled VOCs and urinary concentrations of salbutamol and prednisone showed statistically significant correlations (p<0.01).ConclusionWe have linked exhaled VOCs to urinary detection of salbutamol and OCSs. This merits further development of breathomics into a point-of-care tool for therapeutic drug monitoring.
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
- Eron, Joseph J., et al.
(författare)
-
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
- 2019
-
Ingår i: Antiviral Research. - : Elsevier BV. - 0166-3542 .- 1872-9096. ; 170
-
Tidskriftsartikel (refereegranskat)abstract
- © 2019 The Authors Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL < 50 copies/mL (virologic suppression) and ≥50 copies/mL (VF) (FDA-snapshot analysis). Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF: 3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52–96). Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, respectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2% D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study limitation was the lack of a control arm in the week 96 analysis. Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs, and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF.
|
|
